Review

human adamts13 quantikine elisa kit (R&D Systems)

R&D Systems is a verified supplier

R&D Systems manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

R&D Systems human adamts13 quantikine elisa kit
Human Adamts13 Quantikine Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 14 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+adamts13+quantikine+elisa+kit/Human+ADAMTS13+Quantikine+ELISA+Kit/pm40127394-63-3-8
Average 93 stars, based on 14 article reviews

human adamts13 quantikine elisa kit - by Bioz Stars, 2026-11

93/100 stars

Images

Clinical Proteomics:

Article Title: ADAMTS13 Improves Hepatic Platelet Accumulation in Pyrrolizidine Alkaloids-induced Liver Injury
Article Snippet: .. Plasma ADAMTS13 levels were measured using a Human ADAMTS13 Quantikine ELISA kit (DADT130; R&D Systems, Minneapolis, MN, USA) per the manufacturer’s instructions.23 .. Total RNA was extracted from mouse liver tissues using a Total RNA Kit (DP419; Tiangen, Beijing, China) and synthesized into cDNA using the Superscript II reverse transcriptase kit (TOYOBO, Tokyo, Japan).

Article Title: Distinct impact of IgG subclass on autoantibody pathogenicity in different IgG4-mediated diseases
Article Snippet: .. ADAMTS13 antigen levels in the plasma of HC and TTP patients were measured using Human ADAMTS13 Quantikine ELISA Kit (R&D Systems) according to the manufacturer’s instructions with minor modifications: (1) diluted plasma samples of HC (1:50) and TTP patients (1:2) were used; (2) the range of the standard curve was broadened to 0.78125–100 ng/ml. .. WT C57BL/6, hFCGR-Tg, FcγRα-null, or Fcer1g -/- mice were treated with 10 μg per mouse of TTP1-420 anti-ADAMTS13 antibodies with different constant domains (IgG1/IgG4/N297A/GASDALIE) or control hIgG (Jackson ImmunoResearch Laboratories) on day 0 through tail vein injection.

Article Title: ADAMTS13 Improves Hepatic Platelet Accumulation in Pyrrolizidine Alkaloids-induced Liver Injury
Article Snippet: .. Plasma ADAMTS13 levels were measured using a Human ADAMTS13 Quantikine ELISA kit (DADT130; R&D Systems, Minneapolis, MN, USA) per the manufacturer’s instructions. .. Total RNA was extracted from mouse liver tissues using a Total RNA Kit (DP419; Tiangen, Beijing, China) and synthesized into cDNA using the Superscript II reverse transcriptase kit (TOYOBO, Tokyo, Japan).

Article Title: Distinct impact of IgG subclass and Fc-FcγR interaction on autoantibody pathogenicity in different IgG4-mediated diseases
Article Snippet: .. ADAMTS13 antigen levels in the plasma of HC and TTP patients were measured using Human ADAMTS13 Quantikine ELISA Kit (R&D Systems) according to the manufacturer’s instructions with minor modifications: (1) diluted plasma samples of HC (1:50) and TTP patients (1:2) were used; (2) the range of the standard curve was broadened to 0.78125-100 ng/ml. .. WT C57BL/6, hFCGR Tg , FcγRα null , or Fcer1g -/- mice were treated with 10 μg per mouse of TTP1-420 anti-ADAMTS13 antibodies with different constant domains (IgG1/IgG4/N297A/GASDALIE) or control hIgG (Jackson ImmunoResearch Laboratories) on day 0 through tail vein injection.

Article Title: Distinct impact of IgG subclass on autoantibody pathogenicity in different IgG4-mediated diseases
Article Snippet: .. ADAMTS13 antigen levels in the plasma of HC and TTP patients were measured using Human ADAMTS13 Quantikine ELISA Kit (R&D Systems) according to the manufacturer’s instructions with minor modifications: (1) diluted plasma samples of HC (1:50) and TTP patients (1:2) were used; (2) the range of the standard curve was broadened to 0.78125–100 ng/ml. .. The activity of anti-ADAMTS13 antibodies in mice WT C57BL/6, hFCGR- Tg, FcγRα-null, or Fcer1g-/- mice were treated with 10 μg per mouse of TTP1- 420 anti- ADAMTS13 antibodies with different constant domains (IgG1/IgG4/N297A/GASDALIE) or control hIgG (Jackson ImmunoResearch Laboratories) on day 0 through tail vein injection.

Enzyme-linked Immunosorbent Assay:

Article Title: An Optimized Purification Design for Extracting Active ADAMTS13 from Conditioned Media
Article Snippet: .. 2.5.2. rADAMTS13 Antigen Measurement The quantification of rADAMTS13 in the conditioned media was performed by using the Human ADAMTS13 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA) per the manufacturer’s instructions. ..

Article Title: Development of a protease-resistant ADAMTS13 to improve stability against proteolytic degradation.
Article Snippet: .. Recombinant (r)ADAMTS13 and Human ADAMTS13 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA), Kallikrein, Factor XIIa (Enzyme Research Laboratories, South Bend, IN, USA), Thrombin, Factor Xa, Factor IXa, Factor XIa, Factor VIIa, APC, Elastase, Cathepsin G (Sigma-Aldrich, St. Louis, MO, USA), Proteinase 3 (Enzo Life Sciences, D ow nloaded from http://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2024015212/2362755/bloodadvances.2024015212.pdf by guest on 28 M arch 2025 5 Inc., Farmingdale, NY, USA), FRETS-VWF73 (AnaSpec, Fremont, CA, USA), AEBSF, Sivelestat (Tocris Bioscience, Bristol, UK), Cathepsin G Inhibitor I (Cayman Chemical Company, Ann Arbor, MI, USA). ..

Article Title: ADAMTS13 Improves Hepatic Platelet Accumulation in Pyrrolizidine Alkaloids-induced Liver Injury
Article Snippet: .. Plasma ADAMTS13 levels were measured using a Human ADAMTS13 Quantikine ELISA kit (DADT130; R&D Systems, Minneapolis, MN, USA) per the manufacturer’s instructions. .. Total RNA was extracted from mouse liver tissues using a Total RNA Kit (DP419; Tiangen, Beijing, China) and synthesized into cDNA using the Superscript II reverse transcriptase kit (TOYOBO, Tokyo, Japan).

Article Title: Metalloprotease domain latency protects ADAMTS13 against broad-spectrum inhibitors of metalloproteases while maintaining activity toward VWF.
Article Snippet: J Thromb Haemost.. 2023;21:1789–1801 Abstract Background: ADAMTS13 is a circulating metalloprotease that cleaves von Willebrand factor (VWF) in a shear-dependent manner.. ADAMTS13 is secreted as an active protease but has a long half-life, suggesting that it is resistant to circulating protease inhibitors.

Article Title: Distinct impact of IgG subclass on autoantibody pathogenicity in different IgG4-mediated diseases
Article Snippet: .. ADAMTS13 antigen levels in the plasma of HC and TTP patients were measured using Human ADAMTS13 Quantikine ELISA Kit (R&D Systems) according to the manufacturer’s instructions with minor modifications: (1) diluted plasma samples of HC (1:50) and TTP patients (1:2) were used; (2) the range of the standard curve was broadened to 0.78125–100 ng/ml. .. The activity of anti-ADAMTS13 antibodies in mice WT C57BL/6, hFCGR- Tg, FcγRα-null, or Fcer1g-/- mice were treated with 10 μg per mouse of TTP1- 420 anti- ADAMTS13 antibodies with different constant domains (IgG1/IgG4/N297A/GASDALIE) or control hIgG (Jackson ImmunoResearch Laboratories) on day 0 through tail vein injection.

Recombinant:

Image Search Results

(A) Volcano plots of DEGs (PA-ILI group vs. control group). (B) Heatmap of the top 250 genes between PA-ILI mice (groups P1 & P2) and controls (groups C1 & C2). (C) Dot plots of seven GO biological process categories, including wound healing, hemostasis, coagulation, and platelet-related pathways. (D) Cnetplot displaying 57 DEGs assigned to the seven GO biological process categories. (E) Protein–protein interaction data of VWF from STRING, containing 11 nodes and 104 edges. (F) Venn diagram of 57 DEGs (red) and 11 VWF-related genes (blue) with three shared genes in the overlapping regions, including ADAMTS13. PA-ILI, pyrrolizidine alkaloids-induced liver injury; VWF, von Willebrand factor; DEG, differentially expressed genes; GO, Gene Ontology; STRING, Search Tool for the Retrieval of Interacting Genes/Proteins.

Journal: Journal of Clinical and Translational Hepatology

Article Title: ADAMTS13 Improves Hepatic Platelet Accumulation in Pyrrolizidine Alkaloids-induced Liver Injury

doi: 10.14218/JCTH.2024.00233

Figure Lengend Snippet: (A) Volcano plots of DEGs (PA-ILI group vs. control group). (B) Heatmap of the top 250 genes between PA-ILI mice (groups P1 & P2) and controls (groups C1 & C2). (C) Dot plots of seven GO biological process categories, including wound healing, hemostasis, coagulation, and platelet-related pathways. (D) Cnetplot displaying 57 DEGs assigned to the seven GO biological process categories. (E) Protein–protein interaction data of VWF from STRING, containing 11 nodes and 104 edges. (F) Venn diagram of 57 DEGs (red) and 11 VWF-related genes (blue) with three shared genes in the overlapping regions, including ADAMTS13. PA-ILI, pyrrolizidine alkaloids-induced liver injury; VWF, von Willebrand factor; DEG, differentially expressed genes; GO, Gene Ontology; STRING, Search Tool for the Retrieval of Interacting Genes/Proteins.

Article Snippet: Plasma ADAMTS13 levels were measured using a Human ADAMTS13 Quantikine ELISA kit (DADT130; R&D Systems, Minneapolis, MN, USA) per the manufacturer’s instructions.

Techniques: Control, Coagulation

(A) Representative images (left) and quantification (right) of hepatic ADAMTS13 (red) in patients (n = 3). (B) Plasma level of ADAMTS13 in patients (leftmost). Peripheral platelet count and plasma ADAMTS13 concentration in mild and severe PA-ILI (middle). Relationship between peripheral platelet count and plasma ADAMTS13 in PA-ILI patients (rightmost). (C) Representative Western blots of ADAMTS13 in mouse plasma, lungs, and kidneys. (D) Hepatic mRNA level of ADAMTS13 in MCT-treated mice. (E) Representative Western blots of ADAMTS13 and apoptosis-related proteins. (F) Representative images (left) and quantification (right) of hepatic ADAMTS13 (red) in the mouse liver (n = 3). * p < 0.05, ** p < 0.01, **** p < 0.0001. PA-ILI, pyrrolizidine alkaloids-induced liver injury; DAPI, 4′,6-diamidino-2-phenylindole; MCT, monocrotaline.

Journal: Journal of Clinical and Translational Hepatology

Article Title: ADAMTS13 Improves Hepatic Platelet Accumulation in Pyrrolizidine Alkaloids-induced Liver Injury

doi: 10.14218/JCTH.2024.00233

Figure Lengend Snippet: (A) Representative images (left) and quantification (right) of hepatic ADAMTS13 (red) in patients (n = 3). (B) Plasma level of ADAMTS13 in patients (leftmost). Peripheral platelet count and plasma ADAMTS13 concentration in mild and severe PA-ILI (middle). Relationship between peripheral platelet count and plasma ADAMTS13 in PA-ILI patients (rightmost). (C) Representative Western blots of ADAMTS13 in mouse plasma, lungs, and kidneys. (D) Hepatic mRNA level of ADAMTS13 in MCT-treated mice. (E) Representative Western blots of ADAMTS13 and apoptosis-related proteins. (F) Representative images (left) and quantification (right) of hepatic ADAMTS13 (red) in the mouse liver (n = 3). * p < 0.05, ** p < 0.01, **** p < 0.0001. PA-ILI, pyrrolizidine alkaloids-induced liver injury; DAPI, 4′,6-diamidino-2-phenylindole; MCT, monocrotaline.

Article Snippet: Plasma ADAMTS13 levels were measured using a Human ADAMTS13 Quantikine ELISA kit (DADT130; R&D Systems, Minneapolis, MN, USA) per the manufacturer’s instructions.

Techniques: Clinical Proteomics, Concentration Assay, Western Blot

(A) Representative Western blots and quantification of plasma and hepatic ADAMTS13 protein. (B) Pathological changes in PA-ILI mice treated with rADAMTS13. (C) Measurement of hepatic necrosis (n = 5). (D) Representative images (left) and quantification (right) of hepatic platelets (CD41, red) and VWF deposition (green). * p < 0.05, ** p < 0.01, *** p < 0.001. PA-ILI, pyrrolizidine alkaloids-induced liver injury; VWF, von Willebrand factor; DAPI, 4′,6-diamidino-2-phenylindole; MCT, monocrotaline.

Journal: Journal of Clinical and Translational Hepatology

Article Title: ADAMTS13 Improves Hepatic Platelet Accumulation in Pyrrolizidine Alkaloids-induced Liver Injury

doi: 10.14218/JCTH.2024.00233

Figure Lengend Snippet: (A) Representative Western blots and quantification of plasma and hepatic ADAMTS13 protein. (B) Pathological changes in PA-ILI mice treated with rADAMTS13. (C) Measurement of hepatic necrosis (n = 5). (D) Representative images (left) and quantification (right) of hepatic platelets (CD41, red) and VWF deposition (green). * p < 0.05, ** p < 0.01, *** p < 0.001. PA-ILI, pyrrolizidine alkaloids-induced liver injury; VWF, von Willebrand factor; DAPI, 4′,6-diamidino-2-phenylindole; MCT, monocrotaline.

Article Snippet: Plasma ADAMTS13 levels were measured using a Human ADAMTS13 Quantikine ELISA kit (DADT130; R&D Systems, Minneapolis, MN, USA) per the manufacturer’s instructions.

Techniques: Western Blot, Clinical Proteomics

Figure 1. IgG4 is less pathogenic than IgG1 in anti-ADAMTS13 autoantibodies. (A) Schematic diagram of the experimental design. In brief, wild-type (WT) C57BL/6 or hFCGR-Tg mice were treated with 10 μg of control human IgG (Ctrl hIgG, n≥3), or anti-ADAMTS13 TTP1-420(IgG1) or TTP1-420(IgG4) (n≥4) on day 0 through tail vein injection, blood was collected on day –1, day 1, day 5, and day 8 and analyzed for ADAMTS13 activity. (B–E) Plots showing ADAMTS13 activity in the plasma of WT (B, C) or hFCGR-Tg (D, E) mice treated with the indicated antibodies at the indicated time points and analyzed by the FRETS-VWF73 assay, presented as relative fluorescence units (RFU) changing rates over time (RFU/min) (B, D), and the RFU change within 1 hr on day –1 and day 8 (C, E). Mean ± SEM values are plotted. Two-way ANOVA with Tukey’s (B, D) or Sidak’s (C, E) multiple comparisons tests. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. A representative of two independent experiments is shown.

Journal: eLife

Article Title: Distinct impact of IgG subclass on autoantibody pathogenicity in different IgG4-mediated diseases

doi: 10.7554/elife.76223

Figure Lengend Snippet: Figure 1. IgG4 is less pathogenic than IgG1 in anti-ADAMTS13 autoantibodies. (A) Schematic diagram of the experimental design. In brief, wild-type (WT) C57BL/6 or hFCGR-Tg mice were treated with 10 μg of control human IgG (Ctrl hIgG, n≥3), or anti-ADAMTS13 TTP1-420(IgG1) or TTP1-420(IgG4) (n≥4) on day 0 through tail vein injection, blood was collected on day –1, day 1, day 5, and day 8 and analyzed for ADAMTS13 activity. (B–E) Plots showing ADAMTS13 activity in the plasma of WT (B, C) or hFCGR-Tg (D, E) mice treated with the indicated antibodies at the indicated time points and analyzed by the FRETS-VWF73 assay, presented as relative fluorescence units (RFU) changing rates over time (RFU/min) (B, D), and the RFU change within 1 hr on day –1 and day 8 (C, E). Mean ± SEM values are plotted. Two-way ANOVA with Tukey’s (B, D) or Sidak’s (C, E) multiple comparisons tests. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. A representative of two independent experiments is shown.

Article Snippet: DOI: https://doi.org/10.7554/eLife.76223 17 of 27 Reagent type (species) or resource Designation Source or reference Identifiers Additional information Antibody Anti- Lambda Light Chain Monoclonal Antibody, Biotin (Mouse monoclonal) BD Biosciences Cat# 555794, RRID:AB_396129 ELISA (1:2000) Antibody Anti- Dsg1 TTP1- 8- 15(IgG1) Biotin (human monoclonal) This paper ELISA (1 μg/ml) Antibody Anti- Human IgG- Fc Fragment Antibody HRP (Goat polyclonal) Bethyl Cat# A80- 104P, RRID:AB_67064 ELISA (1:10,000) Antibody Anti- Human IgG1 Hinge- HRP (Mouse monoclonal) SouthernBiotech Cat# 9052–05, RRID:AB_2796619 ELISA (1:3160) Antibody Anti- Human IgG4 Fc- HRP (Mouse monoclonal) SouthernBiotech Cat# 9200–05, RRID:AB_2796691 ELISA (1:3160) Antibody Anti- Human IgG1 Fc Secondary Antibody, HRP (Mouse monoclonal) Thermo Fisher Scientific Cat# MH1715, RRID:AB_10374315 ELISA (1:2000) Antibody Anti- Human IgG4 Fc Secondary Antibody, HRP (Mouse monoclonal) Thermo Fisher Scientific Cat# MH1742, RRID:AB_2539714 ELISA (1:2000) Antibody Anti- Human IgG (H+L) (Goat polyclonal) Jackson ImmunoResearch Labs Cat# 109- 005- 088, RRID:AB_2337539 ELISA (2 μg/ml) Antibody Anti- Human IgG- heavy and light chain Antibody HRP (Goat polyclonal) Bethyl Cat# A80- 219P, RRID:AB_67076 ELISA (1:10,000) Peptide, recombinant protein Streptavidin- HRP BD Biosciences Cat# 554066, RRID:AB_2868972 ELISA (1:1000) Peptide, recombinant protein Recombinant Human ADAMTS13 (Full Length) Protein, CF R&D Systems Cat# 6156- AD ELISA (2 μg/ml) Commercial assay or kit Human ADAMTS13 Quantikine ELISA Kitg R&D Systems Cat# DADT130 Chemical compound, drug FRETS- VWF73 Anaspec Cat# 63728–01 Chemical compound, drug Dispase II Roche Cat# 4942078001 Chemical compound, drug DNase I Sigma Cat# D5025 Chemical compound, drug Collagenase IV Sigma/biosharp Cat# C5138 Software, algorithm GraphPad Prism GraphPad Prism RRID:SCR_002798 Other DAPI stain Invitrogen DD3571 (0.5 μg/ml) Continued

Techniques: Control, Injection, Activity Assay, Clinical Proteomics, Fluorescence

Figure 2. The protective effect of the IgG4 subclass in anti-ADAMTS13 autoantibodies is due to reduced FcγR- mediated antibody effector function. (A) Schematic diagram of the experimental design. In brief, WT, FcγRα- null, Fcer1g-/-, or hFCGR-Tg mice (Ctrl hIgG, n=3~5; anti-ADAMTS13, n=4~5) were treated and analyzed as in Figure 1A. (B–E) Plots showing ADAMTS13 activity in the plasma of WT and FcγRα-null mice (B, C), WT and Fcer1g-/- mice (D, E), WT mice (F, G) or hFCGR-Tg mice (H, I) treated with the indicated antibodies and analyzed at indicated time points as in Figure 1B and C, presented as relative fluorescence units (RFU) changing rates over time (RFU/min) (B, D, F, H), and the RFU change within 1 hr on the indicated days (C, E, G, I). Mean ± SEM values are plotted. Two-way ANOVA with Sidak’s (B–E, G, and I) or Tukey’s (F and H) multiple comparisons tests. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. A representative of two independent experiments is shown.

Journal: eLife

Article Title: Distinct impact of IgG subclass on autoantibody pathogenicity in different IgG4-mediated diseases

doi: 10.7554/elife.76223

Figure Lengend Snippet: Figure 2. The protective effect of the IgG4 subclass in anti-ADAMTS13 autoantibodies is due to reduced FcγR- mediated antibody effector function. (A) Schematic diagram of the experimental design. In brief, WT, FcγRα- null, Fcer1g-/-, or hFCGR-Tg mice (Ctrl hIgG, n=3~5; anti-ADAMTS13, n=4~5) were treated and analyzed as in Figure 1A. (B–E) Plots showing ADAMTS13 activity in the plasma of WT and FcγRα-null mice (B, C), WT and Fcer1g-/- mice (D, E), WT mice (F, G) or hFCGR-Tg mice (H, I) treated with the indicated antibodies and analyzed at indicated time points as in Figure 1B and C, presented as relative fluorescence units (RFU) changing rates over time (RFU/min) (B, D, F, H), and the RFU change within 1 hr on the indicated days (C, E, G, I). Mean ± SEM values are plotted. Two-way ANOVA with Sidak’s (B–E, G, and I) or Tukey’s (F and H) multiple comparisons tests. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. A representative of two independent experiments is shown.

Techniques: Activity Assay, Clinical Proteomics, Fluorescence

Figure 3. ADAMTS13-specific IgG1 levels in the plasma of acquired thrombotic thrombocytopenic purpura (TTP) patients inversely correlate to the ADAMTS13 Ag levels and activity. (A–C) Plots showing ADAMTS13-specific IgG (A), ADAMTS13 activity (B), and ADAMTS13 antigen (C) levels in the plasma of healthy control (HC) (n=23) and acquired TTP patients during the acute phase (n=44). (D) Plot showing correlation analysis of ADAMTS13 activity with ADAMTS13 Ag concentration in TTP patients. (E) ADAMTS13-specific IgG1 (left panel) and IgG4 (right panel) levels in the plasma of TTP patients and HC. (F) Plot showing correlation analysis of ADAMTS13-specific IgG1 with IgG4 levels in TTP patients, with the threshold for IgG1 and IgG4 autoantibodies (two times of HC average values) annotated. (G–J) Plots showing correlation analysis between the anti-ADAMTS13 IgG1 (G, H) and IgG4 (I, J) levels with ADAMTS13 activity (G, I) and ADAMTS13 Ag (H, J) levels in TTP patients, respectively. (K) Plots showing IgG1 and IgG4 anti-ADAMTS13 levels in TTP plasma samples normalized to HC, with IgG1-dominant TTP and IgG4-dominant TTP samples annotated. (L, M) Plot showing ADAMTS13 activity (L) and antigen (M) levels in TTP plasma samples as annotated in (K). Each symbol is derived from an individual plasma sample. Mean ± SEM values are plotted. Unpaired nonparametric Mann-Whitney test (A, B, C, E, L, M) or linear regression analysis (D, F–J). ***p<0.001, ****p<0.0001, ns, non-significant.

Journal: eLife

Article Title: Distinct impact of IgG subclass on autoantibody pathogenicity in different IgG4-mediated diseases

doi: 10.7554/elife.76223

Figure Lengend Snippet: Figure 3. ADAMTS13-specific IgG1 levels in the plasma of acquired thrombotic thrombocytopenic purpura (TTP) patients inversely correlate to the ADAMTS13 Ag levels and activity. (A–C) Plots showing ADAMTS13-specific IgG (A), ADAMTS13 activity (B), and ADAMTS13 antigen (C) levels in the plasma of healthy control (HC) (n=23) and acquired TTP patients during the acute phase (n=44). (D) Plot showing correlation analysis of ADAMTS13 activity with ADAMTS13 Ag concentration in TTP patients. (E) ADAMTS13-specific IgG1 (left panel) and IgG4 (right panel) levels in the plasma of TTP patients and HC. (F) Plot showing correlation analysis of ADAMTS13-specific IgG1 with IgG4 levels in TTP patients, with the threshold for IgG1 and IgG4 autoantibodies (two times of HC average values) annotated. (G–J) Plots showing correlation analysis between the anti-ADAMTS13 IgG1 (G, H) and IgG4 (I, J) levels with ADAMTS13 activity (G, I) and ADAMTS13 Ag (H, J) levels in TTP patients, respectively. (K) Plots showing IgG1 and IgG4 anti-ADAMTS13 levels in TTP plasma samples normalized to HC, with IgG1-dominant TTP and IgG4-dominant TTP samples annotated. (L, M) Plot showing ADAMTS13 activity (L) and antigen (M) levels in TTP plasma samples as annotated in (K). Each symbol is derived from an individual plasma sample. Mean ± SEM values are plotted. Unpaired nonparametric Mann-Whitney test (A, B, C, E, L, M) or linear regression analysis (D, F–J). ***p<0.001, ****p<0.0001, ns, non-significant.

Techniques: Clinical Proteomics, Activity Assay, Control, Concentration Assay, Derivative Assay, MANN-WHITNEY

Review

human adamts13 quantikine elisa kit (R&D Systems)

Structured Review

Images

Related Articles

Clinical Proteomics:

Enzyme-linked Immunosorbent Assay:

Recombinant:

Similar Products

Image Search Results